Yip1 domain family member 6Genealiases: FinGER6 · YIPFalpha3 · Yip4
Q-omics provides the consensus-scored YIPF6 profile across patient tissues and cancer cell-line models. YIPF6 expression is associated with patient survival in 21 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, YIPF6 is differentially expressed in 13, with the highest sampling consensus in THCA. Additionally, YIPF6 RNA expression shows 20,725 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight KIRC, THCA, and UVM as cancer lineages where YIPF6 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for YIPF6 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes YIPF6 survival associations across molecular data types. YIPF6 RNA expression shows survival associations in the most cancer types (21), followed by mutation status (3) and mass-spec protein abundance (8). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible YIPF6 RNA expression–survival associations across cancer types. High YIPF6 expression shows unfavorable associations in UVM, HNSC, KIRP and LUSC, but favorable associations in KIRC and LGG. The KIRC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for YIPF6 RNA expression.
This table summarizes YIPF6 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 13, while mass-spec protein shows differences in 6. The strongest signals are observed in THCA for RNA and HNSC for protein.
This table ranks reproducible tumor–normal expression differences for YIPF6. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. YIPF6 shows lower tumor expression in THCA and higher tumor expression in HNSC, LIHC, LUAD, BRCA and CHOL. The THCA box plot shows higher YIPF6 RNA expression in normal versus tumor tissue (log2 FC = −0.718, t-test p < 0.001).
This table shows molecular features associated with YIPF6 in patient tissues and cancer cell lines. In patient samples, YIPF6 shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set. In cancer cell lines, YIPF6 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BREAST, while CRISPR and shRNA rows add functional-dependency signals in SOFT_TISSUE and BLOOD_Lymphoma.
